He Started a Side Hustle in His Kitchen — Then Took a 'Scary and Crazy' Leap to Grow It to $15 Million Revenue
Up More than 19% In 2022, Is Gilead Sciences Still a Buy? Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy?… Previous Article Bear Market is Back Again… Next Article Virtual Dining Concepts CEO Stephanie Sollers on the Creator Economy
